FDA & Government News

July 23, 2026

FDA Approves Zidesamtinib for ROS1 Lung Cancer

Phase 1/2 ARROS-1 data showed a 44% objective response rate, with most responses ongoing at 6 months.

Conexiant

July 17, 2026

FDA Approves New Iohexol Vials

The approval includes additional 300 mg iodine/mL and 350 mg iodine/mL vial presentations.

Conexiant

June 29, 2026

FDA Approves New Treatment for Thyroid Eye Disease

Phase 3 THRIVE and THRIVE-2 trials supported approval following improvements in proptosis and diplopia in active and chronic disease.

Conexiant

June 26, 2026

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

Conexiant

June 26, 2026

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

June 22, 2026

FDA Clears Olastrocel Trial Expansion

Additional patients with ongoing opioid use are being enrolled as Creative Medical prepares for potential Phase 3 discussions with the FDA.

Conexiant

June 18, 2026

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

Conexiant

June 15, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Conexiant

May 29, 2026

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

Conexiant

April 30, 2026

Urgent Care, Unchecked Power

An unsupervised clinic model and blurred boundaries expose how oversight can fail in outpatient care.

Conexiant

FDA Approves New Iohexol Vials

FDA & Government News

FDA Approves Zidesamtinib for ROS1 Lung Cancer

FDA Approves New Iohexol Vials

FDA Approves New Treatment for Thyroid Eye Disease

FDA Approves New First-Line TNBC Regimen

FDA Monthly Preview: Key July Decisions to Watch

Daily News

FDA Clears Olastrocel Trial Expansion

Top 10 FDA Recalls Physicians Should Know

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

FDA Expands Guselkumab Label in PsA

Urgent Care, Unchecked Power

Recommendations

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Trending Now

FDA Approves New Iohexol Vials

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dentistry

ADA News

CDE World

New Dentist News

Conexiant

AACE Endocrinology AI

Conexiant

GI & Hepatology News

The ASCO Post

JADPRO

JNCCN

JNCCN 360

ASCO AI in Oncology

Glaucoma Physician

Ophthalmology Management

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

The Pathologist

The Medicine Maker

The Analytical Scientist

FDA & Government News

Daily News

Recommendations